Code & Co. provides Tech & Product Due Diligence to Lightrock ahead of its investment in Ultromics, a leader in AI-powered cardiac diagnostics

Ultromics raised $55 million in Series C financing. Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately, using nothing more than a standard ultrasound scan.

Code & Co. assessed Ultromics’ AI platform, reviewing product architecture, AI capabilities, cloud infrastructure, and core technology stack. The evaluation also covered an assessment of the engineering organization and internal processes, including the software development lifecycle and quality management.

Cookie Consent Banner von Real Cookie Banner